The race is on: Will mRNA technology stay attractive for early-stage licensing deals?

Edition

The race is on: Will mRNA technology stay attractive for early-stage licensing deals?

The widespread effectiveness of mRNA-based vaccines has attracted considerable attention to the prospect of mRNA technology serving as a platform that can be used to develop an array of preventative and therapeutic medicines, including vaccines for infectious diseases and cancer treatments. While the extent to which mRNA platforms can be used to develop other drugs remains to be seen, what are the prospects and interest in terms of applicability? How is the current IP landscape around this technology? How are biopharma companies building their mRNA capabilities and in which key areas? Is licensing the favoured way to unlock the full potential of mRNA technologies?

 

Moderator: Klaas P. Zuideveld, CEO, Versameb

Valeria Chiono

Full Professor
Italy
Politecnico di Torino

Dominik Witzigmann

CEO & Co-Founder
Canada
NanoVation Therapeutics

Cees van Rijn

Professor Nanotechnology and Microfluidics
The Netherlands
University of Amsterdam

Luzius Zumstein

Attorney at Law
Switzerland
Vischer

Heinrich Haas

Vice President Formulation & Drug Delivery
Germany
BioNTech
  • No products in the cart.